Biodexa Pharmaceuticals
BDRX
1 hedge funds and large institutions have $72K invested in Biodexa Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
83% less capital invested
Capital invested by funds: $433K → $72K (-$361K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$381K |
| 2 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
-$271 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$123 |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$2 |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $21K | +$225K | +1 | New |
|
|
VF
2
Virtu Financial
New York
| $18K | – | – | – |
|
3
Millennium Management
New York
| $14K | – | – | – |
|
|
CH
4
CVI Holdings
Wilmington,
Delaware
| $11.9K | – | – | – |
|
|
KWM
5
Kingsview Wealth Management
Grants Pass,
Oregon
| $6.49K | – | – | – |
|
6
Morgan Stanley
New York
| $534 | – | – | – |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $70 | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$381K | -1 | Closed |
|
|
CS
9
Credit Suisse
Zurich,
Switzerland
| – | -$1 | – | – |
|
|
10
Group One Trading
Chicago,
Illinois
| – | -$2 | – | – |
|
|
MCC
11
Money Concepts Capital
Palm Beach Gardens,
Florida
| – | -$271 | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$123 | – | – |
|
BDRX Hedge Fund Activity: Q1 2023 in Review
1 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q1 2023, worth a combined $72K — down 83% from $433K a quarter earlier.
Fund positioning in BDRX was balanced in Q1 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $225K. The largest seller was Armistice Capital, exiting entirely with an estimated $381K sold.
- 1 institutional investor held Biodexa Pharmaceuticals (BDRX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $72K of Biodexa Pharmaceuticals stock for Q1 2023, down 83% quarter-over-quarter.
- 1 fund opened new Biodexa Pharmaceuticals positions in Q1 2023 and 1 closed out, a net change of 0 holders.
- The largest Biodexa Pharmaceuticals buyer in Q1 2023 was Renaissance Technologies, an estimated $225K added.
- The largest Biodexa Pharmaceuticals seller in Q1 2023 was Armistice Capital, an estimated $381K sold.
Based on aggregated 13F filings for Q1 2023.